Atlas Trials

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

Clinical trial NCT03944057 · COMPLETED

Trial details

NCT number
NCT03944057
Sponsor
Antengene Corporation
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Relapse/Refractory Multiple Myeloma
Start date
2019-09-02
Primary completion
2022-02-25
Enrollment
82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.